Cimino G, Caridi M, Cardinali V, Sciabolacci S, et al. Venetoclax plus azacitidine as genetic-driven bridge-to-transplant therapy for IDH2-mutated acute myeloid leukaemia (AML) refractory to intensive chemotherapy: proof-of-concept case reports. Ann Hematol 2025;104:4267-4271.
PMID: 40627163